Form 4: CFO Lucy To Granted 2.4M Stock Options in SAB Biotherapeutics

SAB Biotherapeutics' Chief Financial Officer, Lucy To, was granted 2.4 million stock options with an exercise price of $4.45, vesting over four years.

Summary

• Lucy To, Chief Financial Officer of SAB Biotherapeutics, Inc. (SABS), was granted 2,400,000 stock options.
• The options have an exercise price of $4.45 per share.
• The grant date for these options was February 3, 2026.
• The options were granted under the company's 2021 Omnibus Equity Incentive Plan, as amended.
• The vesting schedule is 1/4 on the one-year anniversary of the grant date (February 3, 2027), with the remaining 3/4 vesting pro rata monthly over the subsequent 36 months.
• The options expire on February 3, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents standard executive compensation and aligns management incentives, but does not provide new operational or financial performance data.

Positives

• Granting of significant stock options to the CFO aligns management's interests with long-term shareholder value.
• The options are part of an existing equity incentive plan, indicating a structured approach to executive compensation.

Negatives

• No immediate cash inflow for the CFO, as these are options, not shares.
• The value of the options is contingent on the stock price exceeding the exercise price of $4.45.

Risks

• The value of the options is subject to the future performance of SAB Biotherapeutics' stock price.
• If the stock price does not exceed $4.45, the options may expire worthless.

Future Outlook

This filing is a Form 4, which reports an insider transaction and does not typically contain forward-looking statements or guidance about the company's future operational or financial performance.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the CFO is a common practice in the biotechnology industry, aiming to incentivize long-term performance and retention. This aligns executive compensation with shareholder interests, a standard governance practice.

Comparison to Industry Standards

• The grant of 2.4 million options to a CFO in a biotech company like SAB Biotherapeutics is a substantial equity award, comparable to grants seen in similar-sized or growth-stage biotech firms where equity compensation forms a significant part of the total compensation package.
• The four-year vesting schedule with a one-year cliff and monthly pro-rata thereafter is a standard industry practice designed to encourage long-term commitment and performance.
• The exercise price being at or above the market price on the grant date (implied, as it's an option grant) is typical for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of management's interests with shareholder value creation. Dilution risk if all options are exercised in the future, though this is standard for equity compensation plans.
• Employees: May signal confidence in the company's future and the value of its equity compensation programs.

Next Steps

• The options will begin vesting on February 3, 2027.
• The remaining options will vest monthly over the subsequent 36 months.
• The CFO may choose to exercise vested options before the expiration date of February 3, 2036.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for SAB Biotherapeutics. It aligns management incentives but provides no new data on operational performance or financial health to warrant a change in recommendation.

Keywords

SAB Biotherapeutics, SABS, Stock Options, Equity Incentive Plan, CFO, Insider Transaction, Form 4, Executive Compensation, Biotechnology